Pacific Edge posts $14.5m loss as it awaits US Medicare decisions

Pacific Edge posts $14.5m loss as it awaits US Medicare decisions
Pacific Edge chief executive Peter Meintjes says as each day passes, he feels more confident about a favourable decision from Novitas. (Image: Supplied)
John Anthony
Dunedin-headquartered cancer diagnostics company Pacific Edge has posted a $14.5 million after-tax loss for the six months to September 30.The NZX and ASX-listed company said it was awaiting outcomes of several events that had the potential to renew growth in Cxbladder, its urine-based genomic biomarker test for the detection and surveillance of bladder cancer. The events include:Novitas, the Medicare Administrative Contractor (MAC) with responsibility for Pacific Edge’s US lab, making a favourable policy decision on a Local Coverage...

More Markets

NZ sharemarket ends week up nearly 1.2%
Markets Market close

NZ sharemarket ends week up nearly 1.2%

The S&P/NZX 50 Index closed at 12,904.11, up 149.96 points or 1.18%.

Graham Skellern 20 Dec 2024
Marlborough Wine Estates' NZX delisting gets green light
Markets

Marlborough Wine Estates' NZX delisting gets green light

Cost savings were behind the decision to delist, the company says.

John Anthony 20 Dec 2024
Global private equity firm snaps up 50% of Craigs
Markets

Global private equity firm snaps up 50% of Craigs

Partnership with TA Associates tipped to accelerate Craigs' growth.

John Anthony 20 Dec 2024
ComCom delays Manawa takeover deal decision
Markets

ComCom delays Manawa takeover deal decision

Due on Dec 24, the decision will now be in March.

Ian Llewellyn 20 Dec 2024